SCHEMBL1106716

SCHEMBL1106716

Cc1cocc(C)c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31464904 0.79 NQO1 (0.34)
SCHEMBL426079 0.78
SCHEMBL9944597 0.77 GABRA1 (0.30)
SCHEMBL14999211 0.72 GABRA1 (0.32)
SCHEMBL8986270 0.67
SCHEMBL9331058 0.65 NQO1 (0.34)
SCHEMBL6629957 0.65
SCHEMBL8833394 0.65
SCHEMBL17205088 0.65
SCHEMBL14304289 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025020304-A1 CATALYST COMPONENT FOR OLEFIN POLYMERIZATION, CATALYST AND USE OF CATALYST 中国石油天然气股份有限公司 2025-01-30 WO claimed
US-11744816-B2 Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease ESPERION THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230210800-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS INC (US) 2023-07-06 US disclosed
US-20180133177-A1 Treatment of NASH with Gemcabene NEUROBO PHARMACEUTICALS, INC. 2018-05-17 US disclosed
US-20180064671-A1 Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease GLAS AMERICAS LLC 2018-03-08 US disclosed
US-9855240-B2 Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2018-01-02 US disclosed
US-9849104-B2 Treatment of NASH with gemcabene GEMPHIRE THERAPEUTICS INC. (US) 2017-12-26 US disclosed
US-20170349516-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. 2017-12-07 US disclosed
US-20170172955-A1 Treatment of Mixed Dyslipidemia NEUROBO PHARMACEUTICALS, INC. 2017-06-22 US disclosed
US-20170172954-A1 Treatment of NASH with Gemcabene NEUROBO PHARMACEUTICALS, INC. 2017-06-22 US disclosed
US-20110237511-A1 EP4 Receptor Agonist, Compositions and Methods Thereof MERCK FROSST CANADA (CA) 2011-09-29 US disclosed
US-20110195978-A1 COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE PURDUE RESEARCH FOUNDATION (US) 2011-08-11 US disclosed
US-7994330-B2 Oxidizing p-xylene to terephthalic acid using a catalyst having a dicarboximide skeleton; hydrothermally treating the product with hot water, decomposing and removing catalyst impurities DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2011-08-09 US disclosed
US-20110071314-A1 PROCESS FOR PRODUCING AROMATIC POLYCARBOXYLIC ACID DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2011-03-24 US disclosed
US-20110003860-A1 HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES ESPERION THERAPEUTICS, INC. 2011-01-06 US disclosed
US-7524986-B2 Methods for producing aromatic carboxylic acids DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2009-04-28 US disclosed
US-20080171881-A1 Method for Producing Organic Compound and Method for Decomposing Compound Having Dicarboximide Skeleton DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2008-07-17 US disclosed
EP-1870394-A1 METHOD FOR PRODUCING ORGANIC COMPOUND AND METHOD FOR DECOMPOSING COMPOUND HAVING DICARBOXYIMIDE SKELETON Daicel Chemical Industries, Ltd. (JP) 2007-12-26 EP disclosed
US-20070191634-A1 Methods for producing aromatic carboxylic acids DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2007-08-16 US disclosed
EP-1734029-A1 PROCESS FOR PRODUCING AROMATIC CARBOXYLIC ACID Daicel Chemical Industries, Ltd. (JP) 2006-12-20 EP disclosed